Research
Hormonal
Metabolic surgery (specifically Roux-en-Y gastric bypass) yields higher remission rates than adjustable gastric banding, independent of the amount of weight lost.
For obese patients considering surgery, Roux-en-Y gastric bypass offers significantly higher remission rates than adjustable gastric banding, even if the weight loss is similar. This is due to hormonal changes in the gut, not just calorie restriction.
GoodSupportsHIGH confidence
Diabetic remission was associated with postoperative weight loss, but subjects receiving RYGB were twice as likely to have diabetes remission than laparoscopic adjustable gastric banding (LAGB) even after adjusting for weight change.
Why this rating
Supported by multiple RCTs and meta-analyses.
Source
Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus
Jinyoung Kim et al. · Diabetes & Metabolism Journal · 2022
DOI 10.4093/dmj.2021.0377
narrative_reviewCited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Significant weight loss (induced by metabolic surgery, very-low-calorie diets, or intensive insulin therapy) prior to irreversible beta-cell damage can induce durable remission of type 2 diabetes, defined as HbA1c <6.5% without medication.Good
- Newer diabetes medications, specifically GLP-1 receptor agonists (like tirzepatide) and SGLT2 inhibitors, facilitate diabetes remission through significant weight loss and glycemic control, though long-term remission data is still emerging.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →